CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives

While more than half of non-Hodgkin lymphomas (NHL) can be cured with modern frontline chemoimmunotherapy regimens, outcomes of relapsed and/or refractory (r/r) disease in subsequent lines remain poor, particularly if considered ineligible for hematopoietic stem cell transplantation. Hence, r/r NHLs...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheikh, Semira, Migliorini, Denis, Lang, Noémie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405554/
https://www.ncbi.nlm.nih.gov/pubmed/36009506
http://dx.doi.org/10.3390/biomedicines10081960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405554/
https://www.ncbi.nlm.nih.gov/pubmed/36009506
http://dx.doi.org/10.3390/biomedicines10081960

Ejemplares similares